




Advancing Therapeutics.
Improving Lives.



September 3, 2015

Mr Balaji UD
Sr Director – Global HIV/AIDS Initiatives
Emcure Pharmaceuticals Ltd
A-203, Ganga Osian Square, Survey No. 249+250
Wakad, Pune 411057
India

RE: TAF Combination Products

To Whom it May Concern:

Reference is made to that certain Amended and Restated License Agreement between Emcure Pharmaceuticals Ltd (“you”), the Medicines Patent Pool Foundation and Gilead Sciences, Inc. (“Gilead”), dated as of September 17, 2014, and to any subsequent modification thereof (the “License Agreement”). All capitalized terms used in this letter but not defined herein shall have the meanings assigned to such terms in the License Agreement.

This letter is to clarify that Section 2.5(b)(ii) of the License Agreement is not intended to prohibit you from manufacturing or selling any TAF Combination Products following Gilead’s receipt of Marketing Approval for the TAF Quad. Accordingly, following Gilead’s receipt of Marketing Approval by the FDA for the TAF Quad, Gilead hereby agrees that your manufacture or sale of any TAF Combination Product (including without limitation the TAF Quad) in accordance with the terms of the License Agreement will not constitute a breach of Section 2.5(b)(ii) of the License Agreement.

If you have any further questions, please contact Kushendra Chaudhary at kchaudhary@medicinespatentpool.org.

Kind Regards,

Clifford Samuel
Senior Vice President
Access Operations & Emerging Markets
Gilead Sciences, Inc.

Greg Perry
Executive Director
Medicines Patent Pool Foundation